Slide 1: Defining the Future of Life-Saving Diagnostics at the Point of Care
Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | January 2022 © 2022 Hyperfine, Inc.
Slide 2: Forward Looking Statements
© 2022 Hyperfine, Inc. Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine’s actual results may differ from its expectations, estimates and projections
Slide 3: Preliminary Financial Information
© 2022 Hyperfine, Inc. Preliminary Financial Information The preliminary financial information included in this presentation is unaudited and is subject to completion of Hyperfine’s quarter and year-end closing procedures and further financial review. In certain cases, Hyperfine has provided expecte
Slide 4: Today, brain diagnostics are single point-in-time and delay door to discharge
4 Today, brain diagnostics are single point-in-time and delay the time from door to discharge. Our mission is to transform patient care by creating access to life-saving diagnostics and actionable data at the point-of-care.
Slide 5: The Hyperfine Ecosystem
The Hyperfine Ecosystem 13 A full ecosystem solution: Hardware, software, consumables and applications powered by artificial intelligence Democratizing Imaging, Sensing, and Guided Intervention to cover the care continuum Sensing (in development) Imaging (FDA cleared) Intervention (in development)
Slide 6: Imaging, Sensing, and Guided Intervention are Large Markets Poised for Disruption
Imaging, Sensing, and Guided Intervention are Large Markets Poised for Disruption 13 $23B $22B $28B Imaging Hospitals, Outpatient >100,000 Potential installation targets Sensing ICUs, Expanded Hospital, Surgical Centers, Outpatient, At-home ~4M Potential unit sales Guided Intervention Hospitals and
Slide 7: We are Transforming Medical Imaging with Swoop
We are Transforming Medical Imaging with Swoop® Swoop is the world's first FDA-cleared portable MRI system™ 11 MRI 1.0 1980 MRI 2.0 1990 MRI 3.0 FDA Cleared 2020
Slide 8: Swoop is the Next Generation of MRI
Swoop® is the Next Generation of MRI 12 Installed base of 70 units* as of year-end 2021 Current primary clinical uses: - Hydrocephalus and Pediatrics - Neuro ICU Follow-Up and Post-Operative - Stroke Portable low-field MRI Patent protected noise cancellation system enables clinical-grade images FDA
Slide 9: Swoop Brings MRI to the Patient
Swoop® Brings MRI to the Patient 16 Acute Care Settings • Swoop is designed to enable rapid diagnoses and treatment for patients regardless of income, resources, or location • Produces high-quality images at low magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patien
Slide 10: Clinical & Workflow Benefits
Clinical & Workflow Benefits
Slide 11: Numerous challenges with conventional MRI
Numerous challenges with conventional MRI : 14 Adverse events occur in 22-46% of cases during transport High-cost limits accessibility Complex site requirements and upgrades Scheduling delays lead to longer length of stay Consumption of valuable personnel resources Risk of adverse events during tran
Slide 12: Hyperfine Workflow Benefits
Hyperfine Workflow Benefits 15 MRI ordered Patient preparation Intra-hospital transfer to MRI MRI examination Intra-hospital transfer to unit Post MRI examination Traditional MRI workflow (25.8 hours) MRI ordered MRI examination Post MRI examination Hyperfine workflow (90mins, 94% reduction in total
Slide 13: Swoop Clinical Use Cases Today
© 2021 HYPERFINE Intensive Care Unit - Acute Mental Status Change - Ataxia - Cerebral Edema - Cerebrovascular Disease - Cranial Neuropathy - Extra Ventricular Drain Placement - Follow-up Intracranial Hemorrhage - Follow-up Ischemic Stroke - Follow-up Hematoma - Stroke - Tumor Pre- and Post-Op Emerge
Slide 14: Clinical Validation of Hyperfine
Clinical Validation of Hyperfine 20 Game changer is a good way to put it […] being able to do the level of sophisticated imaging in an ICU that MRI can provide.’’ Dr. Fady Charbel, MD, FAANS, FACS Hyperfine provides me with an opportunity to acquire the information, to interpret the information, and
Slide 15: Use Case: Stroke
Use Case: Stroke HYPERFINE
Slide 16: Hyperfine Provides Compelling Platform for Stroke Diagnosis
Hyperfine Provides Compelling Platform for Stroke Diagnosis 18 15 million people worldwide suffer a stroke annually Stroke is the 2nd leading cause of death globally 87% strokes are ischemic strokes MRI scans are better at detecting ischemic stroke damage compared to CT scans MRI use for stroke has
Slide 17: Stroke Diagnosis Confirmed
Stroke Diagnosis Confirmed 19 62-year-old male Presented with new left sided weakness and tremor
Slide 18: Use Case: Hydrocephalus
Use Case: Hydrocephalus
Slide 19: Radiation Exposure and Imaging Access for Hydrocephalus Shunt-Checks is an Overlooked Problem
Problem: Children can receive 1-12 CTs1 each year, increasing their risk for radiation-associated malignancy2 High field MRI is generally more resource intensive and expensive to perform than CT 50% of shunts fail in <2 years and 98% of shunts fail by year 10.3 Hydrocephalus: The buildup of fluid in
Slide 20: Hydrocephalus: Swoop's Potential from Early Cases
Hydrocephalus: Swoop’s Potential from Early Cases 5 y/o presents to Neurosurgery clinic with headache. Swoop scan performed in the clinic demonstrates ventricular catheter (without artifact from valve) along with enlarged ventricles – child admitted to hospital for shunt revision immediately, saving
Slide 21: Pipeline Opportunities
Pipeline Opportunities HYPERFINE
Slide 22: Innovative R&D Engine Designed to Expand Product Roadmap
Innovative R&D Engine Designed to Expand Product Roadmap 24 Stroke Hydrocephalus Extremities Intra and Post Operative Expanded Addressable Market Improved usability Automated Stroke Detection Lower cost of goods Existing applications V1 Potential future applications V2 C-spine Potential benefits:
Slide 23: Developing a Non-Invasive Brain Vital Sensor
Developing a Non-Invasive Brain Vital Sensor 26 Breakthrough AEGTM Technology designed to unlock access to blood flow and pressure Non-Invasive Non-invasive use on every patient to enable broader access and earlier diagnosis Continuous Trend Analysis Designed for continuous sensing to build trends f
Slide 24: Brain-Sensing Clinical Opportunities
Brain-Sensing Clinical Opportunities 27 Intensive Care Unit Emergency Department Operating Room Outpatient & At Home - Hydrocephalus - Vasospasm - Stroke - Cerebral edema - Traumatic Brain Injury - Subarachnoid hemorrhage - Suspected seizures - Acute liver failure - Altered mental status - Brain tum
Slide 25: Financial Profile
Financial Profile HYPERFINE
Slide 26: 2021 Preliminary Financial Results & Total Installed Units
2021 Preliminary Financial Results* & Total Installed Units • Approximately $1.42 to $1.50 million preliminary unaudited 2021 total revenue • Realized approximately $1.45 million in grant funding for the full year 2021 as part of grant fulfillment for Swoop installations *See slide above titled “Pre
Slide 27: 2021: A Milestone Year
2021: A Milestone Year • July: Announced Definitive Agreement to be Listed on Nasdaq through a Business Combination with HealthCor Catalio Acquisition Corp. • August: Swoop® Demonstrates High Accuracy for Detection of Brain Hemorrhage in Study Published in Nature Communications • September: Announce
Slide 28: Leadership Team
Leadership Team HYPERFINE
Slide 29: Management Team with Proven Track Record of Success
Management Team with Proven Track Record of Success 35 Dave Scott Chief Executive Officer Alok Gupta Chief Financial Officer Dr. Khan Siddiqui Chief Strategy Officer & Chief Medical Officer Tom Teisseyre Chief Product Officer Mark Hughes Chief Operating Officer Scott White Chief Commercial Officer K
Slide 30: Thank You!
Thank You! a ( ) ieee pyperfine Swoop | table MRI systen : Tt we af HYPERFINE
Slide 31: Appendix
Appendix HYPERFINE
Slide 32: Brain is the Largest MRI Market with Nearly 25% of MR Procedures
Brain is the Largest MRI Market with Nearly 25% of MR Procedures N = 27.4 Million Procedures MR Procedure Mix, All Sites, by Percent, 2020 Distribution of MR Sites and Procedures, by Site Type, 2020 3,025 1,765 445 1,000 2,930 8.4 1.8 5.0 6.8 5.4 Spine Breast Chest Pelvis & Abdomen (including liver)